Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Interest & Investment Income (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Interest & Investment Income for 3 consecutive years, with $8739.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 121.03% to $8739.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$59821.0, a 100.8% decrease, with the full-year FY2024 number at $1.8 million, up 31.21% from a year prior.
  • Interest & Investment Income was $8739.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$128602.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $5.7 million in Q3 2023 to a low of -$128602.0 in Q2 2025.
  • A 3-year average of $922431.0 and a median of $20683.5 in 2024 define the central range for Interest & Investment Income.
  • Biggest YoY gain for Interest & Investment Income was 121.03% in 2025; the steepest drop was 959.52% in 2025.
  • 60 Degrees Pharmaceuticals' Interest & Investment Income stood at $5.7 million in 2023, then tumbled by 99.54% to $26405.0 in 2024, then plummeted by 66.9% to $8739.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Interest & Investment Income are $8739.0 (Q3 2025), -$128602.0 (Q2 2025), and $33637.0 (Q1 2025).